Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms I-SABR
- 23 Jan 2018 Status changed from active, no longer recruiting to recruiting.
- 23 Jan 2018 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 17 Jan 2018 Status changed from recruiting to active, no longer recruiting.